Login / Signup

Immunogenicity and safety of mixed COVID-19 vaccine regimens in patients with immune-mediated inflammatory diseases: a single-centre prospective cohort study.

Carol A HitchonChristine MesaCharles N BernsteinKathryn C FitzgeraldCatherine CardSheila F O'BrienJohn Kim
Published in: BMJ open (2023)
Heterologous COVID-19 vaccination improves seroconversion rates following a vector vaccine and does not lead to IMID disease flare. IMIDs benefit from at least three vaccines.
Keyphrases
  • coronavirus disease
  • sars cov
  • oxidative stress
  • respiratory syndrome coronavirus